Chapter 3

David Kirby, Evidence of Harm Mercury in Vaccines and the Autism Epidemic: A Medical Controversy, (New York, NY: St. Martin’s Griffin, 2005).

Robert F. Kennedy Jr. et al., Thimerosal: Let the Science Speak: The Evidence Supporting the Immediate Removal of Mercury―a Known Neurotoxin―from Vaccines, (New York, NY: Skyhorse, 2015).

Trace Amounts: Autism, Mercury, and the Hidden Truth, directed by Eric Gladen and Shiloh Levine, (Arlington: Gathr Films, 2014), DVD.

“Historical Development of the Mercury Based Preservative Thimerosal,” Children’s Health Defense, accessed September 12, 2022.

David A. Geier et al., “Thimerosal: Clinical, Epidemiologic and Biochemical Studies,” Clinica Chimica Acta, 444 (2015): 212-20, doi:10.1016/j.cca.2015.02.030.

Neal A. Halsey, “Limiting Infant Exposure to Thimerosal in Vaccines and Other Sources of Mercury,” Journal of the American Medical Association 282, no. 18 (1999): 1763–1766, doi:10.1001/jama.282.18.1763.

Put Children First, “Thimerosal Timeline,” accessed on September 19, 2022.

Put Children First, “Thimerosal Timeline,” accessed on September 19, 2022.

Thomas M. Verstraeten et al., “Increased Risk of Developmental Neurological Impairment After High Exposure to Thimerosal-Containing Vaccine in First Month of Life,” Epidemic Intelligence Service, accessed on September 24, 2022.

Thomas M. Verstraeten et al., “Increased Risk of Developmental Neurological Impairment After High Exposure to Thimerosal-Containing Vaccine in First Month of Life,” Epidemic Intelligence Service, accessed on September 24, 2022.

Thomas M. Verstraeten et al., “Increased Risk of Developmental Neurological Impairment After High Exposure to Thimerosal-Containing Vaccine in First Month of Life,” Epidemic Intelligence Service, accessed on September 24, 2022.

Thomas M. Verstraeten et al., “Increased Risk of Developmental Neurological Impairment After High Exposure to Thimerosal-Containing Vaccine in First Month of Life,” Epidemic Intelligence Service, accessed on September 24, 2022.

Thomas M. Verstraeten et al., “Increased Risk of Developmental Neurological Impairment After High Exposure to Thimerosal-Containing Vaccine in First Month of Life,” Epidemic Intelligence Service, accessed on September 24, 2022.

Thomas M. Verstraeten et al., “Scientific Review of Vaccine Safety Datalink Information,” (transcript, Simpsonwood Retreat Center, Norcross, Georgia, June 7-8, 2000)

Thomas M. Verstraeten et al., “Scientific Review of Vaccine Safety Datalink Information,” (transcript, Simpsonwood Retreat Center, Norcross, Georgia, June 7-8, 2000)

Thomas M. Verstraeten et al., “Scientific Review of Vaccine Safety Datalink Information,” (transcript, Simpsonwood Retreat Center, Norcross, Georgia, June 7-8, 2000)

Thomas M. Verstraeten, et al., “Safety of Thimerosal-Containing Vaccines: A Two-Phased Study of Computerized Health Maintenance Organization Databases,” Pediatrics 112, no. 5 (2003): 1039-1048, doi:10.1542/peds.112.5.1039.

Thomas M. Verstraeten, et al., “Safety of Thimerosal-Containing Vaccines: A Two-Phased Study of Computerized Health Maintenance Organization Databases,” Pediatrics 112, no. 5 (2003): 1039-1048, doi:10.1542/peds.112.5.1039.

Thomas M. Verstraeten, “Thimerosal, the Centers for Disease Control and Prevention, and GlaxoSmithKline,” Pediatrics 113, no. 4 (2004): 932, doi:10.1542./peds..113.4.932.

Institute of Medicine (US) Immunization Safety Review Committee, Immunization Safety Review: Vaccines and Autism (Washington DC: National Academies Press (US), 2004), doi:10.17226/10997.

Brian Hooker et al., “Methodological Issues and Evidence of Malfeasance in Research Purporting to Show Thimerosal in Vaccines is Safe,” BioMed Research International 2014, (2014): 247218, doi:10.1155/2014/247218.

Kreesten M. Madsen, et al. 2003. “Thimerosal and the Occurrence of Autism: Negative Ecological Evidence from Danish Population-Based Data.” American Academy of Pediatrics 112, no. 3 Pt 1: 604-606. doi:10.1542/peds.112.3.604.

Kreesten M. Madsen, et al. 2003. “Thimerosal and the Occurrence of Autism: Negative Ecological Evidence from Danish Population-Based Data.” American Academy of Pediatrics 112, no. 3 Pt 1: 604-606. doi:10.1542/peds.112.3.604.

Put Children First, “Thimerosal Timeline,” accessed on September 19, 2022.

Put Children First, “Thimerosal Timeline,” accessed on September 19, 2022.

Heather A. Young, David A. Geier and Mark R. Geier, “Thimerosal Exposure in Infants and Neurodevelopmental Disorders: An Assessment of Computerized Medical Records in the Vaccine Safety Datalink,” Journal of the Neurological Sciences 271, no. 1-2 (2008): 110-118. doi:10.1016/j.jns.2008.04.002.

Heather A. Young, David A. Geier and Mark R. Geier, “Thimerosal Exposure in Infants and Neurodevelopmental Disorders: An Assessment of Computerized Medical Records in the Vaccine Safety Datalink,” Journal of the Neurological Sciences 271, no. 1-2 (2008): 110-118. doi:10.1016/j.jns.2008.04.002.

David A. Geier et al., “A Two-Phase Study Evaluating the Relationship Between Thimerosal-Containing Vaccine Administration and the Risk for an Autism Spectrum Disorder Diagnosis in the United States,” Translational Neurodegeneration 2, no. 1 (2013): 25, doi:10.1186/2047-9158-2-25.

David A. Geier et al., “Thimerosal-Containing Hepatitis B Vaccination and the Risk for Diagnosed Specific Delays in Development in the United States: A Case-Control Study in the Vaccine Safety Datalink,” North American Journal of Medical Sciences 6, no. 10 (2014): 519-531, doi:10.4103/1947-2714.143284.